+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Refractory Anemia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768015
  • Report
  • April 2019
  • Region: Global
  • 70 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Baxter International Inc
  • Celgene Corp
  • Johnson & Johnson
  • Nohla Therapeutics Inc
  • Novartis AG
  • Onconova Therapeutics Inc
  • MORE
The global clinical trial report- “2019 Refractory Anemia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Refractory Anemia. It presents in-depth analysis of Refractory Anemia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Refractory Anemia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Refractory Anemia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Refractory Anemia

The research work is prepared through extensive and continuous research on Refractory Anemia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Refractory Anemia patients are identified
  • The report includes panorama of Refractory Anemia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Refractory Anemia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Baxter International Inc
  • Celgene Corp
  • Johnson & Johnson
  • Nohla Therapeutics Inc
  • Novartis AG
  • Onconova Therapeutics Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Refractory Anemia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Refractory Anemia Clinical Trials by Region
2.2.2 Average Enrollment of Refractory Anemia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Refractory Anemia Treatment, 2019

3. Region wise Refractory Anemia Clinical Trials
3.1 Asia Pacific Refractory Anemia Clinical Trials by Country
3.2 Europe Refractory Anemia Clinical Trials by Country
3.3 North America Refractory Anemia Clinical Trials by Country
3.4 Middle East and Africa Refractory Anemia Clinical Trials by Country
3.5 South and Central America Refractory Anemia Clinical Trials by Country

4. Refractory Anemia Clinical Trial Trends
4.1 Start Year wise Refractory Anemia Clinical Trials
4.2 Phase wise Refractory Anemia Clinical Trials
4.3 Trial Status wise Refractory Anemia Clinical Trials
4.4 Trial Type wise Refractory Anemia Clinical Trials

5. Refractory Anemia Average Enrollment Trends
5.1 Average Enrollment in Refractory Anemia Trials by Year
5.2 Average Enrollment in Refractory Anemia Trials by Phase
5.3 Average Enrollment in Refractory Anemia Trials by Status
5.4 Average Enrollment in Refractory Anemia Trials by Type of Trial

6. Companies Participating in Refractory Anemia Clinical Trials
6.1 Refractory Anemia Trials by Sponsor Type
6.2 Refractory Anemia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Refractory Anemia Trials- Phase 1
7.2 Refractory Anemia Trials- Phase 2
7.3 Refractory Anemia Trials- Phase 3
7.4 Refractory Anemia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Refractory Anemia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Refractory Anemia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Refractory Anemia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Refractory Anemia Clinical Trials and Enrolment
Figure 7: North America - Country wise Refractory Anemia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Refractory Anemia Clinical Trials and Enrolment
Figure 9: Refractory Anemia Clinical Trials by Phase
Figure 10: Refractory Anemia Clinical Trials by Trial Status
Figure 11: Refractory Anemia Clinical Trials by Type
Figure 12: Refractory Anemia Clinical Trials by Sponsor Type
Figure 13: Refractory Anemia Clinical Trials by Leading Sponsors
Figure 14: Refractory Anemia Average Enrollment by Phase
Figure 15: Refractory Anemia Average Enrollment by Trial Status
Figure 16: Refractory Anemia Average Enrollment by Type
Figure 17: Refractory Anemia- Average Enrolment by Type of Sponsors
Figure 18: Refractory Anemia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Refractory Anemia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Refractory Anemia Clinical Trials and Enrolment
Table 5: Europe - Country wise Refractory Anemia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Refractory Anemia Clinical Trials and Enrolment
Table 7: North America - Country wise Refractory Anemia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Refractory Anemia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Refractory Anemia Average Enrollment by Phase
Table 15: Refractory Anemia Average Enrollment by Trial Status
Table 16: Refractory Anemia Average Enrollment by Type
Table 17: Refractory Anemia- Average Enrolment by Type of Sponsors
Table 18: Refractory Anemia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actinium Pharmaceuticals Inc
  • Baxter International Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Celgene Corp
  • Johnson & Johnson
  • Nohla Therapeutics Inc
  • Novartis AG
  • Onconova Therapeutics Inc
  • Sanofi
  • SymBio Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll